Catabasis Pharmaceuticals Inc.

Catabasis Pharmaceuticals is drawing on research showing that salicylate, a close relative of aspirin, improves glucose homeostasis in people living with type 2 diabetes. Catabasis hopes that by combining salicylate with optimized forms of omega-3 fatty acids, it can come up with a safe and reimbursable drug that simultaneously inhibits pro-inflammatory pathways and activates anti-inflammatory pathways, with benefits for diabetes, dyslipidemia, and inflammatory diseases.